Renal impairment as a risk factor for trifluridine/tipiracil-induced adverse events in metastatic colorectal cancer patients from the REGOTAS study.
Humans
Uracil
/ therapeutic use
Retrospective Studies
Trifluridine
/ adverse effects
Frontotemporal Dementia
/ drug therapy
Colorectal Neoplasms
/ pathology
Thymine
/ therapeutic use
Pyrrolidines
/ adverse effects
Colonic Neoplasms
/ drug therapy
Rectal Neoplasms
/ drug therapy
Drug Combinations
Risk Factors
Neutropenia
/ chemically induced
Antineoplastic Combined Chemotherapy Protocols
/ adverse effects
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
20 10 2023
20 10 2023
Historique:
received:
21
06
2023
accepted:
17
10
2023
medline:
31
10
2023
pubmed:
21
10
2023
entrez:
20
10
2023
Statut:
epublish
Résumé
Renal impairment may be associated with an increased risk of hematologic events (AEs) in patients undergoing treatment with trifluridine/tipiracil (FTD/TPI). This study aimed to investigate the specific types of AEs linked to renal impairment in patients with metastatic colorectal cancer (mCRC) receiving FTD/TPI, using real-world data. Among the patients included in the REGOTAS study (a retrospective study of FTD/TPI versus regorafenib), those treated with FTD/TPI were evaluated. Creatinine clearance values of < 30, 30-60, 60-90, and > 90 mL/min were defined as severe, moderate, mild renal impairment, and normal renal function, respectively. Renal impairment was analyzed as a risk factor for grade 3 or higher AEs using a logistic regression model. Overall survival (OS) and progression-free survival (PFS) based on renal impairment were evaluated. A total of 309 patients were included in the analysis, with 124, 130, and 55 patients divided into the normal, mild, and moderate-to-severe groups, respectively. The risk of grade 3 or higher neutropenia was significantly higher in the moderate-to-severe group (odds ratio 3.47; 95% confidence interval 1.45-8.30; P = 0.005), but there was no significant increase in the risk of non-hematologic AEs in any of the groups. The OS and PFS of patients in the mild and moderate-to-severe groups were comparable to those in the normal group. Patients with mCRC and moderate/severe renal impairment receiving FTD/TPI therapy may develop severe neutropenia; however, FTD/TPI remains a viable treatment option due to its clinical benefit.
Identifiants
pubmed: 37863951
doi: 10.1038/s41598-023-45244-7
pii: 10.1038/s41598-023-45244-7
pmc: PMC10589204
doi:
Substances chimiques
tipiracil
NGO10K751P
Uracil
56HH86ZVCT
Trifluridine
RMW9V5RW38
Thymine
QR26YLT7LT
Pyrrolidines
0
Drug Combinations
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
17931Informations de copyright
© 2023. Springer Nature Limited.
Références
Mayer, R. J. et al. Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N. Engl. J. Med. 372, 1909–1919 (2015).
doi: 10.1056/NEJMoa1414325
pubmed: 25970050
Tanaka, N. et al. Repeated oral dosing of TAS-102 confers high trifluridine incorporation into DNA and sustained antitumor activity in mouse models. Oncol. Rep. 32, 2319–2326 (2014).
doi: 10.3892/or.2014.3487
pubmed: 25230742
pmcid: 4240496
Saif, M. W. et al. A phase I, open-label study evaluating the safety and pharmacokinetics of trifluridine/tipiracil in patients with advanced solid tumors and varying degrees of renal impairment. Cancer Chemother. Pharmacol. 88, 485–497 (2021).
doi: 10.1007/s00280-021-04308-z
pubmed: 34097100
Yoshino, T. et al. Post-marketing surveillance study of trifluridine/tipiracil in patients with metastatic colorectal cancer. Jpn. J. Clin. Oncol. 51, 700–706 (2021).
doi: 10.1093/jjco/hyaa243
pubmed: 33438718
Moriwaki, T. et al. Propensity Score Analysis of Regorafenib Versus Trifluridine/Tipiracil in Patients with Metastatic Colorectal Cancer Refractory to Standard Chemotherapy (REGOTAS): A Japanese Society for Cancer of the Colon and Rectum Multicenter Observational Study. Oncologist 23, 7–15 (2018).
doi: 10.1634/theoncologist.2017-0275
pubmed: 28894015
Cancer Therapy Evaluation Program, National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) v4.0. https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm (2010).
Yoshino, T. et al. TAS-102 monotherapy for pretreated metastatic colorectal cancer: A double-blind, randomised, placebo-controlled phase 2 trial. Lancet Oncol 13, 993–1001 (2012).
doi: 10.1016/S1470-2045(12)70345-5
pubmed: 22951287
Shitara, K. et al. Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 19, 1437–1448 (2018).
doi: 10.1016/S1470-2045(18)30739-3
pubmed: 30355453
Van Cutsem, E. et al. Pooled safety analysis from phase III studies of trifluridine/tipiracil in patients with metastatic gastric or gastroesophageal junction cancer and metastatic colorectal cancer. ESMO Open 7, 100633 (2022).
doi: 10.1016/j.esmoop.2022.100633
pubmed: 36455504
pmcid: 9808443
Shitara, K. et al. Efficacy and safety of trifluridine/tipiracil in older and younger patients with metastatic gastric or gastroesophageal junction cancer: Subgroup analysis of a randomized phase 3 study (TAGS). Gastric Cancer 25, 586–597 (2022).
doi: 10.1007/s10120-021-01271-9
pubmed: 34997449
pmcid: 9013328
Yoshino, T. et al. Neutropenia and survival outcomes in metastatic colorectal cancer patients treated with trifluridine/tipiracil in the RECOURSE and J003 trials. Ann. Oncol. 31, 88–95 (2020).
doi: 10.1016/j.annonc.2019.10.005
pubmed: 31912801
Funakoshi, Y. et al. Prediction of glomerular filtration rate in cancer patients by an equation for Japanese estimated glomerular filtration rate. Jpn. J. Clin. Oncol. 43, 271–277 (2013).
doi: 10.1093/jjco/hys235
pubmed: 23329851